Skip to main content
Terug
SLNO logo

Soleno Therapeutics, Inc.

Datakwaliteit: 100%
SLNO
NASDAQ Healthcare Biotechnology
€ 31,72
▼ € 1,50 (-4,52%)
Marktkapitalisatie: 1,70B
Dagbereik
€ 31,72 € 34,16
52-Weeksbereik
€ 31,71 € 90,32
Volume
951.302
50D / 200D Gem.
€ 39,76 / € 59,33
Vorige Slotkoers
€ 33,22

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 81,6 0,4
P/B 3,8 2,9
ROE % 6,0 3,8
Net Margin % 11,0 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 101,20 +219.0%
Low: € 60,00 High: € 125,00
Forward K/W
8,2
Forward WPA
€ 3,89
WPA Groei (sch.)
+0,0%
Omzet Sch.
470 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 16,04
€ 14,31 – € 18,79
1,6 B 5
FY2029 € 12,81
€ 11,43 – € 15,01
1,4 B 2
FY2028 € 9,18
€ 4,72 – € 13,23
1 B 7

Belangrijkste Punten

Debt/Equity of 0,01 — conservative balance sheet
Generating 46,73M in free cash flow
P/E of 81,55 — premium valuation
Cash machine — converts 223,67% of earnings into free cash flow
Capital efficient — spends only 0,04% of revenue on capex
ROIC of 2,48% — low return on invested capital

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
6,01%
ROIC2,48%
Net Margin10,97%
Op. Margin7,85%

Veiligheid

Debt / Equity
0,01
Current Ratio5,80
Interest Coverage2,73

Waardering

P/E Ratio
81,55
P/B Ratio3,78
EV/EBITDA109,45
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 190,41M Net Income (TTM) 20,89M
ROE 6,01% ROA 3,71%
Gross Margin 98,58% Operating Margin 7,85%
Net Margin 10,97% Free Cash Flow (TTM) 46,73M
ROIC 2,48% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 5,80
Interest Coverage 2,73 Dividend Yield 0,00%
Valuation
P/E Ratio 81,55 P/B Ratio 3,78
P/S Ratio 8,95 PEG Ratio -1,08
EV/EBITDA 109,45 Dividend Yield 0,00%
Market Cap 1,70B Enterprise Value 1,64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 190,41M 0,0 0,0 0,0 0,0
Net Income 20,89M -175,85M -38,99M -24,07M -30,91M
EPS (Diluted) 0,39 -4,38 -2,36 -2,87 -5,81
Gross Profit 187,71M 0,0 0,0 0,0 0,0
Operating Income 14,95M -187,67M -41,38M -24,40M -31,53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 563,83M 330,97M 180,69M 26,50M 35,55M
Total Liabilities 113,72M 85,86M 23,18M 16,15M 17,76M
Shareholders' Equity 450,12M 245,11M 157,51M 10,35M 17,79M
Total Debt 2,69M 52,83M 403.000,0 155.000,0 457.000,0
Cash & Equivalents 70,11M 87,93M 169,68M 14,60M 21,30M
Current Assets 355,81M 293,89M 171,36M 15,65M 22,42M
Current Liabilities 61,36M 18,75M 11,51M 7,31M 8,01M